Crisugabalin vs Mirogabalin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Diabetic Peripheral Neuropathic Pain

Shared mechanism: α2δ-1 subunit of voltage-gated calcium channels · full Diabetic Peripheral Neuropathic Pain pipeline

Crisugabalin

Marketed by Haisco Pharmaceutical Group

Phase 3 in Diabetic Peripheral Neuropathic Painsmall molecule
Reliable signal

NCT04647773 · Phase 2/3 · status unknown

Adaptive Phase 2/3, multicentre, double-blind trial controlled by placebo and pregabalin (725 patients randomised). At week 13 both recommended doses (40 and 80 mg/d) reduced the average daily pain score more than placebo (-2.24 and -2.16 vs -1.23; both P < .001).

Next expected readout: August 2028 · NCT07859111 (registry estimate)

Reported efficacy

Change from baseline in Average Daily Pain Score (ADPS) at Week 13: Week 13 change from baseline in average daily pain score (pooled stages): crisugabalin 40 mg/d -2.24 and 80 mg/d -2.16 vs placebo -1.23 (both P < .001) (met)

Result source: NCT04647773

Mirogabalin

Marketed by Daiichi Sankyo and partners

Phase 3 in Diabetic Peripheral Neuropathic Painsmall molecule
Partial signal

NCT02318706 · Phase 3 · completed

Participants were randomized to three mirogabalin doses or placebo and treatment was double-blinded, with 834 randomized participants. The primary clinical pain endpoint had mixed results: the 30-mg dose was significantly better than placebo, while the 15-mg and 20-mg comparisons were not statistically significant, so the findings provide meaningful but mixed evidence.

Next expected readout: March 2027 · NCT07451431 (registry estimate)

Reported efficacy

Average Daily Pain Score (ADPS) (Baseline to Week 14): Average Daily Pain Score (ADPS) change from baseline to week 14, LS mean difference vs placebo: -0.39 (95% CI: -0.74, -0.04), p = 0.0301 (met)

Result source: NCT04094662

Results for Diabetic Peripheral Neuropathic Pain

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCrisugabalinMirogabalin
Average daily pain, change—Trial running · NCT07859111-1.8 vs -1.5−0.2 vs placebo30 mg/Day · wk 7 · n 90NCT01504412
20 other results
  • -1.7 vs -1.4 30 mg/Day · wk 6 · n 90 · Phase 2 · primary NCT01504412
  • -1.5 vs -1.3 30 mg/Day · wk 5 · n 90 · Phase 2 · primary NCT01504412
  • -1.6 vs -1.1 30 mg/Day · wk 4 · n 90 · Phase 2 · primary NCT01504412
  • -1.4 vs -1.1 30 mg/Day · wk 3 · n 90 · Phase 2 · primary NCT01504412
  • -1.1 vs -0.9 30 mg/Day · wk 2 · n 90 · Phase 2 · primary NCT01504412
  • -0.6 vs -0.6 30 mg/Day · wk 1 · n 90 · Phase 2 · primary NCT01504412
  • -1.9 vs -1.5 20 mg/Day · wk 7 · n 93 · Phase 2 · primary NCT01504412
  • -1.8 vs -1.4 20 mg/Day · wk 6 · n 93 · Phase 2 · primary NCT01504412
  • -1.7 vs -1.3 20 mg/Day · wk 5 · n 93 · Phase 2 · primary NCT01504412
  • -1.6 vs -1.1 20 mg/Day · wk 4 · n 93 · Phase 2 · primary NCT01504412
  • -1.5 vs -1.1 20 mg/Day · wk 3 · n 93 · Phase 2 · primary NCT01504412
  • -1.2 vs -0.9 20 mg/Day · wk 2 · n 93 · Phase 2 · primary NCT01504412
  • -0.9 vs -0.6 20 mg/Day · wk 1 · n 93 · Phase 2 · primary NCT01504412
  • -1.8 vs -1.5 10 mg/Day · wk 7 · n 90 · Phase 2 · primary NCT01504412
  • -1.8 vs -1.4 10 mg/Day · wk 6 · n 90 · Phase 2 · primary NCT01504412
  • -1.6 vs -1.3 10 mg/Day · wk 5 · n 90 · Phase 2 · primary NCT01504412
  • -1.5 vs -1.1 10 mg/Day · wk 4 · n 90 · Phase 2 · primary NCT01504412
  • -1.3 vs -1.1 10 mg/Day · wk 3 · n 90 · Phase 2 · primary NCT01504412
  • -1.2 vs -0.9 10 mg/Day · wk 2 · n 90 · Phase 2 · primary NCT01504412
  • -0.7 vs -0.6 10 mg/Day · wk 1 · n 90 · Phase 2 · primary NCT01504412
30% pain reduction—Trial running · NCT07859111—Not posted · NCT04094662
50% pain reduction—Trial running · NCT07859111—Not posted · NCT04094662
Sleep interference, change—Trial running · NCT07859111—Not posted · NCT04094662

Average daily pain, change

Crisugabalin
—Trial running · NCT07859111
Mirogabalin
-1.8 vs -1.5−0.2 vs placebo30 mg/Day · wk 7 · n 90NCT01504412
20 other results
  • -1.7 vs -1.4 30 mg/Day · wk 6 · n 90 · Phase 2 · primary NCT01504412
  • -1.5 vs -1.3 30 mg/Day · wk 5 · n 90 · Phase 2 · primary NCT01504412
  • -1.6 vs -1.1 30 mg/Day · wk 4 · n 90 · Phase 2 · primary NCT01504412
  • -1.4 vs -1.1 30 mg/Day · wk 3 · n 90 · Phase 2 · primary NCT01504412
  • -1.1 vs -0.9 30 mg/Day · wk 2 · n 90 · Phase 2 · primary NCT01504412
  • -0.6 vs -0.6 30 mg/Day · wk 1 · n 90 · Phase 2 · primary NCT01504412
  • -1.9 vs -1.5 20 mg/Day · wk 7 · n 93 · Phase 2 · primary NCT01504412
  • -1.8 vs -1.4 20 mg/Day · wk 6 · n 93 · Phase 2 · primary NCT01504412
  • -1.7 vs -1.3 20 mg/Day · wk 5 · n 93 · Phase 2 · primary NCT01504412
  • -1.6 vs -1.1 20 mg/Day · wk 4 · n 93 · Phase 2 · primary NCT01504412
  • -1.5 vs -1.1 20 mg/Day · wk 3 · n 93 · Phase 2 · primary NCT01504412
  • -1.2 vs -0.9 20 mg/Day · wk 2 · n 93 · Phase 2 · primary NCT01504412
  • -0.9 vs -0.6 20 mg/Day · wk 1 · n 93 · Phase 2 · primary NCT01504412
  • -1.8 vs -1.5 10 mg/Day · wk 7 · n 90 · Phase 2 · primary NCT01504412
  • -1.8 vs -1.4 10 mg/Day · wk 6 · n 90 · Phase 2 · primary NCT01504412
  • -1.6 vs -1.3 10 mg/Day · wk 5 · n 90 · Phase 2 · primary NCT01504412
  • -1.5 vs -1.1 10 mg/Day · wk 4 · n 90 · Phase 2 · primary NCT01504412
  • -1.3 vs -1.1 10 mg/Day · wk 3 · n 90 · Phase 2 · primary NCT01504412
  • -1.2 vs -0.9 10 mg/Day · wk 2 · n 90 · Phase 2 · primary NCT01504412
  • -0.7 vs -0.6 10 mg/Day · wk 1 · n 90 · Phase 2 · primary NCT01504412

30% pain reduction

Crisugabalin
—Trial running · NCT07859111
Mirogabalin
—Not posted · NCT04094662

50% pain reduction

Crisugabalin
—Trial running · NCT07859111
Mirogabalin
—Not posted · NCT04094662

Sleep interference, change

Crisugabalin
—Trial running · NCT07859111
Mirogabalin
—Not posted · NCT04094662
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Crisugabalin
Week 13 change from baseline in average daily pain score (pooled stages): crisugabalin 40 mg/d -2.24 and 80 mg/d -2.16 vs placebo -1.23 (both P < .001) NCT04647773 · Phase 2/3 · design grade: strong · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Crisugabalin: 0 of 4 rows · Mirogabalin: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricMirogabalin
Dropout rate
14.5%30 mg (15 mg BID)a
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
show 12 more results
10.7%20 mg (10 mg BID)
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
7.2%15 mg QD
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
13.3%Moderate Renal Impairment
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
20%Severe Renal Impairment
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
14.4%30 mg/Day
NCT01504412 · Phase 2 · registry result, not featured evidence
20.2%20 mg/Day
NCT01504412 · Phase 2 · registry result, not featured evidence
4.4%10 mg/Day
NCT01504412 · Phase 2 · registry result, not featured evidence
22.8%15 mg QD
NCT01496365 · Phase 2 · registry result, not featured evidence
10.5%15 mg BID
NCT01496365 · Phase 2 · registry result, not featured evidence
17.9%10 mg BID
NCT01496365 · Phase 2 · registry result, not featured evidence
7%10 mg QD
NCT01496365 · Phase 2 · registry result, not featured evidence
10.5%5mg QD
NCT01496365 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
6%30 mg (15 mg BID)a
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
show 12 more results
1.8%20 mg (10 mg BID)
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
2.4%15 mg QD
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
13.3%Moderate Renal Impairment
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
0%Severe Renal Impairment
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
11.1%30 mg/Day
NCT01504412 · Phase 2 · registry result, not featured evidence
7.4%20 mg/Day
NCT01504412 · Phase 2 · registry result, not featured evidence
1.1%10 mg/Day
NCT01504412 · Phase 2 · registry result, not featured evidence
8.8%15 mg QD
NCT01496365 · Phase 2 · registry result, not featured evidence
7%15 mg BID
NCT01496365 · Phase 2 · registry result, not featured evidence
10.7%10 mg BID
NCT01496365 · Phase 2 · registry result, not featured evidence
3.5%10 mg QD
NCT01496365 · Phase 2 · registry result, not featured evidence
5.3%5mg QD
NCT01496365 · Phase 2 · registry result, not featured evidence
Serious AEs
6.7%30 mg (15 mg BID)a
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
show 12 more results
4.8%20 mg (10 mg BID)
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
2.4%15 mg QD
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
3.3%Moderate Renal Impairment
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
0%Severe Renal Impairment
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
2.2%30 mg/Day
NCT01504412 · Phase 2 · registry result, not featured evidence
4.3%20 mg/Day
NCT01504412 · Phase 2 · registry result, not featured evidence
1.1%10 mg/Day
NCT01504412 · Phase 2 · registry result, not featured evidence
3.8%15 mg QD
NCT01496365 · Phase 2 · registry result, not featured evidence
0%15 mg BID
NCT01496365 · Phase 2 · registry result, not featured evidence
1.8%10 mg BID
NCT01496365 · Phase 2 · registry result, not featured evidence
5.4%10 mg QD
NCT01496365 · Phase 2 · registry result, not featured evidence
3.6%5mg QD
NCT01496365 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
30 mg (15 mg BID)a
nasopharyngitis 16.4% (placebo 12.7%)
somnolence 14.5% (placebo 3.9%)
dizziness 10.9% (placebo 2.1%)
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
show 12 more results
20 mg (10 mg BID)
nasopharyngitis 14.5% (placebo 12.7%)
somnolence 12.1% (placebo 3.9%)
dizziness 8.5% (placebo 2.1%)
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
15 mg QD
nasopharyngitis 13.4% (placebo 12.7%)
somnolence 8.5% (placebo 3.9%)
dizziness 4.9% (placebo 2.1%)
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
nasopharyngitis 20%
somnolence 13.3%
back pain 6.7%
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
nasopharyngitis 40%
oedema peripheral 20%
back pain 0%
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
30 mg/Day
somnolence 21.1% (placebo 5.7%)
dizziness 16.7% (placebo 3.4%)
oedema peripheral 7.8% (placebo 1.1%)
NCT01504412 · Phase 2 · registry result, not featured evidence
20 mg/Day
nasopharyngitis 14% (placebo 3.4%)
somnolence 14% (placebo 5.7%)
dizziness 10.8% (placebo 3.4%)
NCT01504412 · Phase 2 · registry result, not featured evidence
10 mg/Day
somnolence 8.9% (placebo 5.7%)
nasopharyngitis 7.8% (placebo 3.4%)
dizziness 5.6% (placebo 3.4%)
NCT01504412 · Phase 2 · registry result, not featured evidence
15 mg QD
dizziness 11.3% (placebo 1.9%)
fatigue 7.5% (placebo 1.9%)
somnolence 5.7% (placebo 0.9%)
NCT01496365 · Phase 2 · registry result, not featured evidence
15 mg BID
dizziness 15.8% (placebo 1.9%)
somnolence 12.3% (placebo 0.9%)
balance disorder 5.3% (placebo 0%)
NCT01496365 · Phase 2 · registry result, not featured evidence
10 mg BID
headache 8.9% (placebo 3.7%)
somnolence 8.9% (placebo 0.9%)
dizziness 7.1% (placebo 1.9%)
NCT01496365 · Phase 2 · registry result, not featured evidence
10 mg QD
dizziness 12.5% (placebo 1.9%)
constipation 8.9% (placebo 1.9%)
headache 7.1% (placebo 3.7%)
NCT01496365 · Phase 2 · registry result, not featured evidence
5mg QD
headache 10.9% (placebo 3.7%)
diarrhoea 5.5% (placebo 2.8%)
nausea 3.6% (placebo 1.9%)
NCT01496365 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 8 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Mirogabalin

ADPS -0.6 vs -0.26 placebo score @ 1wk30 mg (15 mg BID)
absolute change · score
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
show 66 more results
-1 vs -0.46 placebo score @ 2wk30 mg (15 mg BID)
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.33 vs -0.57 placebo score @ 3wk30 mg (15 mg BID)
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.43 vs -0.7 placebo score @ 4wk30 mg (15 mg BID)
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.48 vs -0.84 placebo score @ 5wk30 mg (15 mg BID)
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.58 vs -0.92 placebo score @ 6wk30 mg (15 mg BID)
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.57 vs -1.03 placebo score @ 7wk30 mg (15 mg BID)
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.53 vs -1.09 placebo score @ 8wk30 mg (15 mg BID)
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.63 vs -1.16 placebo score @ 9wk30 mg (15 mg BID)
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.67 vs -1.18 placebo score @ 10wk30 mg (15 mg BID)
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.69 vs -1.25 placebo score @ 11wk30 mg (15 mg BID)
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.82 vs -1.28 placebo score @ 12wk30 mg (15 mg BID)
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.85 vs -1.32 placebo score @ 13wk30 mg (15 mg BID)
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.88 vs -1.37 placebo score @ 14wk30 mg (15 mg BID)
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-0.4 vs -0.26 placebo score @ 1wk20 mg (10 mg BID)
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-0.72 vs -0.46 placebo score @ 2wk20 mg (10 mg BID)
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-0.84 vs -0.57 placebo score @ 3wk20 mg (10 mg BID)
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-0.94 vs -0.7 placebo score @ 4wk20 mg (10 mg BID)
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.06 vs -0.84 placebo score @ 5wk20 mg (10 mg BID)
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.13 vs -0.92 placebo score @ 6wk20 mg (10 mg BID)
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.13 vs -1.03 placebo score @ 7wk20 mg (10 mg BID)
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.26 vs -1.09 placebo score @ 8wk20 mg (10 mg BID)
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.27 vs -1.16 placebo score @ 9wk20 mg (10 mg BID)
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.33 vs -1.18 placebo score @ 10wk20 mg (10 mg BID)
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.36 vs -1.25 placebo score @ 11wk20 mg (10 mg BID)
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.36 vs -1.28 placebo score @ 12wk20 mg (10 mg BID)
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.43 vs -1.32 placebo score @ 13wk20 mg (10 mg BID)
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.47 vs -1.37 placebo score @ 14wk20 mg (10 mg BID)
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-0.39 vs -0.26 placebo score @ 1wk15 mg QD
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-0.6 vs -0.46 placebo score @ 2wk15 mg QD
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-0.78 vs -0.57 placebo score @ 3wk15 mg QD
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-0.87 vs -0.7 placebo score @ 4wk15 mg QD
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-0.97 vs -0.84 placebo score @ 5wk15 mg QD
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.01 vs -0.92 placebo score @ 6wk15 mg QD
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.06 vs -1.03 placebo score @ 7wk15 mg QD
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.07 vs -1.09 placebo score @ 8wk15 mg QD
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.13 vs -1.16 placebo score @ 9wk15 mg QD
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.19 vs -1.18 placebo score @ 10wk15 mg QD
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.23 vs -1.25 placebo score @ 11wk15 mg QD
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.24 vs -1.28 placebo score @ 12wk15 mg QD
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.27 vs -1.32 placebo score @ 13wk15 mg QD
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.34 vs -1.37 placebo score @ 14wk15 mg QD
NCT02318706 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-2.66 vs -1.86 placebo score @ 5wk15 mg QD
NCT01496365 · Phase 2 · registry result, not featured evidence
-1.13 vs -0.55 placebo score @ 1wk15 mg QD
NCT01496365 · Phase 2 · registry result, not featured evidence
-1.76 vs -1.12 placebo score @ 2wk15 mg QD
NCT01496365 · Phase 2 · registry result, not featured evidence
-2.3 vs -1.47 placebo score @ 3wk15 mg QD
NCT01496365 · Phase 2 · registry result, not featured evidence
-2.46 vs -1.67 placebo score @ 4wk15 mg QD
NCT01496365 · Phase 2 · registry result, not featured evidence
-2.79 vs -1.86 placebo score @ 5wk15 mg BID
NCT01496365 · Phase 2 · registry result, not featured evidence
-1.4 vs -0.55 placebo score @ 1wk15 mg BID
NCT01496365 · Phase 2 · registry result, not featured evidence
-2.33 vs -1.12 placebo score @ 2wk15 mg BID
NCT01496365 · Phase 2 · registry result, not featured evidence
-2.55 vs -1.47 placebo score @ 3wk15 mg BID
NCT01496365 · Phase 2 · registry result, not featured evidence
-2.72 vs -1.67 placebo score @ 4wk15 mg BID
NCT01496365 · Phase 2 · registry result, not featured evidence
-2.32 vs -1.86 placebo score @ 5wk10 mg QD
NCT01496365 · Phase 2 · registry result, not featured evidence
-2.64 vs -1.86 placebo score @ 5wk10 mg BID
NCT01496365 · Phase 2 · registry result, not featured evidence
-0.95 vs -0.55 placebo score @ 1wk10 mg QD
NCT01496365 · Phase 2 · registry result, not featured evidence
-1.26 vs -0.55 placebo score @ 1wk10 mg BID
NCT01496365 · Phase 2 · registry result, not featured evidence
-1.56 vs -1.12 placebo score @ 2wk10 mg QD
NCT01496365 · Phase 2 · registry result, not featured evidence
-1.72 vs -1.12 placebo score @ 2wk10 mg BID
NCT01496365 · Phase 2 · registry result, not featured evidence
-1.78 vs -1.47 placebo score @ 3wk10 mg QD
NCT01496365 · Phase 2 · registry result, not featured evidence
-2.38 vs -1.47 placebo score @ 3wk10 mg BID
NCT01496365 · Phase 2 · registry result, not featured evidence
-2.41 vs -1.67 placebo score @ 4wk10 mg QD
NCT01496365 · Phase 2 · registry result, not featured evidence
-2.68 vs -1.67 placebo score @ 4wk10 mg BID
NCT01496365 · Phase 2 · registry result, not featured evidence
-2.04 vs -1.86 placebo score @ 5wk5mg QD
NCT01496365 · Phase 2 · registry result, not featured evidence
-0.68 vs -0.55 placebo score @ 1wk5mg QD
NCT01496365 · Phase 2 · registry result, not featured evidence
-1.38 vs -1.12 placebo score @ 2wk5mg QD
NCT01496365 · Phase 2 · registry result, not featured evidence
-1.62 vs -1.47 placebo score @ 3wk5mg QD
NCT01496365 · Phase 2 · registry result, not featured evidence
-2.01 vs -1.67 placebo score @ 4wk5mg QD
NCT01496365 · Phase 2 · registry result, not featured evidence
ADPS -0.14 score @ 1wk
absolute change · score
No placebo or comparator arm
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
show 28 more results
-0.2 score @ 1wk
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-0.37 score @ 2wk
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-0.5 score @ 2wk
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-0.85 score @ 3wk
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.83 score @ 3wk
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.13 score @ 4wk
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-2.07 score @ 4wk
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-0.9 score @ 5wk
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.89 score @ 5wk
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-0.92 score @ 6wk
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.82 score @ 6wk
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.22 score @ 7wk
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.93 score @ 7wk
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.29 score @ 8wk
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-2.04 score @ 8wk
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.36 score @ 9wk
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-2.21 score @ 9wk
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.33 score @ 10wk
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-2.32 score @ 10wk
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.43 score @ 11wk
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-2.07 score @ 11wk
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.59 score @ 12wk
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-2.1 score @ 12wk
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.84 score @ 13wk
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-2.25 score @ 13wk
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-1.9 score @ 14wk
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-2.52 score @ 14wk
NCT02607280 · Phase 3 · monotherapy · Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain · phase 3
-0.39 score @ 14wk
NCT04094662 · Phase 3 · sponsor-reported, not registry data
Pain NRS -0.6 vs -0.59 placebo score @ 1wk30 mg/Day
absolute change · score
NCT01504412 · Phase 2 · registry result, not featured evidence
show 20 more results
-1.06 vs -0.86 placebo score @ 2wk30 mg/Day
NCT01504412 · Phase 2 · registry result, not featured evidence
-1.35 vs -1.05 placebo score @ 3wk30 mg/Day
NCT01504412 · Phase 2 · registry result, not featured evidence
-1.56 vs -1.12 placebo score @ 4wk30 mg/Day
NCT01504412 · Phase 2 · registry result, not featured evidence
-1.47 vs -1.28 placebo score @ 5wk30 mg/Day
NCT01504412 · Phase 2 · registry result, not featured evidence
-1.68 vs -1.41 placebo score @ 6wk30 mg/Day
NCT01504412 · Phase 2 · registry result, not featured evidence
-1.75 vs -1.5 placebo score @ 7wk30 mg/Day
NCT01504412 · Phase 2 · registry result, not featured evidence
-0.88 vs -0.59 placebo score @ 1wk20 mg/Day
NCT01504412 · Phase 2 · registry result, not featured evidence
-1.21 vs -0.86 placebo score @ 2wk20 mg/Day
NCT01504412 · Phase 2 · registry result, not featured evidence
-1.5 vs -1.05 placebo score @ 3wk20 mg/Day
NCT01504412 · Phase 2 · registry result, not featured evidence
-1.65 vs -1.12 placebo score @ 4wk20 mg/Day
NCT01504412 · Phase 2 · registry result, not featured evidence
-1.68 vs -1.28 placebo score @ 5wk20 mg/Day
NCT01504412 · Phase 2 · registry result, not featured evidence
-1.78 vs -1.41 placebo score @ 6wk20 mg/Day
NCT01504412 · Phase 2 · registry result, not featured evidence
-1.91 vs -1.5 placebo score @ 7wk20 mg/Day
NCT01504412 · Phase 2 · registry result, not featured evidence
-0.69 vs -0.59 placebo score @ 1wk10 mg/Day
NCT01504412 · Phase 2 · registry result, not featured evidence
-1.16 vs -0.86 placebo score @ 2wk10 mg/Day
NCT01504412 · Phase 2 · registry result, not featured evidence
-1.32 vs -1.05 placebo score @ 3wk10 mg/Day
NCT01504412 · Phase 2 · registry result, not featured evidence
-1.5 vs -1.12 placebo score @ 4wk10 mg/Day
NCT01504412 · Phase 2 · registry result, not featured evidence
-1.62 vs -1.28 placebo score @ 5wk10 mg/Day
NCT01504412 · Phase 2 · registry result, not featured evidence
-1.79 vs -1.41 placebo score @ 6wk10 mg/Day
NCT01504412 · Phase 2 · registry result, not featured evidence
-1.82 vs -1.5 placebo score @ 7wk10 mg/Day
NCT01504412 · Phase 2 · registry result, not featured evidence
SF-MPQ -24.2 vs -16.7 placebo score @ 7wk30 mg/Day
absolute change · score
NCT01504412 · Phase 2 · registry result, not featured evidence
show 2 more results
-22.1 vs -16.7 placebo score @ 7wk20 mg/Day
NCT01504412 · Phase 2 · registry result, not featured evidence
-21.9 vs -16.7 placebo score @ 7wk10 mg/Day
NCT01504412 · Phase 2 · registry result, not featured evidence
ADPS -2.9 vs -1.91 placebo score @ 5wk15 mg QD
absolute change · score
End of treatment
NCT01496365 · Phase 2 · registry result, not featured evidence
show 4 more results
-2.79 vs -1.91 placebo score @ 5wk15 mg BID
End of treatment
NCT01496365 · Phase 2 · registry result, not featured evidence
-2.4 vs -1.91 placebo score @ 5wk10 mg QD
End of treatment
NCT01496365 · Phase 2 · registry result, not featured evidence
-2.87 vs -1.91 placebo score @ 5wk10 mg BID
End of treatment
NCT01496365 · Phase 2 · registry result, not featured evidence
-2.05 vs -1.91 placebo score @ 5wk5mg QD
End of treatment
NCT01496365 · Phase 2 · registry result, not featured evidence
Pain 30 66.7% (n=51) vs 41.7% (n=108) placebo @ 5wk15 mg QD
responder rate · % of participants
Responder rate: ≥30% decrease from baseline · Yes
NCT01496365 · Phase 2 · registry result, not featured evidence · converted to % from 34 Participants as posted
show 4 more results
56.1% (n=57) vs 41.7% (n=108) placebo @ 5wk*15 mg BID
Responder rate: ≥30% decrease from baseline · Yes
NCT01496365 · Phase 2 · registry result, not featured evidence · converted to % from 32 Participants as posted
57.1% (n=56) vs 41.7% (n=108) placebo @ 5wk*10 mg QD
Responder rate: ≥30% decrease from baseline · Yes
NCT01496365 · Phase 2 · registry result, not featured evidence · converted to % from 32 Participants as posted
60.7% (n=56) vs 41.7% (n=108) placebo @ 5wk*10 mg BID
Responder rate: ≥30% decrease from baseline · Yes
NCT01496365 · Phase 2 · registry result, not featured evidence · converted to % from 34 Participants as posted
40% (n=55) vs 41.7% (n=108) placebo @ 5wk*5mg QD
Responder rate: ≥30% decrease from baseline · Yes
NCT01496365 · Phase 2 · registry result, not featured evidence · converted to % from 22 Participants as posted
ADSI -2.97 vs -1.98 placebo score @ 5wk15 mg QD
absolute change · score
NCT01496365 · Phase 2 · registry result, not featured evidence
show 4 more results
-2.69 vs -1.98 placebo score @ 5wk15 mg BID
NCT01496365 · Phase 2 · registry result, not featured evidence
-2.35 vs -1.98 placebo score @ 5wk10 mg QD
NCT01496365 · Phase 2 · registry result, not featured evidence
-2.52 vs -1.98 placebo score @ 5wk10 mg BID
NCT01496365 · Phase 2 · registry result, not featured evidence
-2.19 vs -1.98 placebo score @ 5wk5mg QD
NCT01496365 · Phase 2 · registry result, not featured evidence
SF-MPQ Sensory -6.86 vs -6.29 placebo score @ 5wk15 mg QD
absolute change · score
Sensory score
NCT01496365 · Phase 2 · registry result, not featured evidence
show 4 more results
-8.55 vs -6.29 placebo score @ 5wk15 mg BID
Sensory score
NCT01496365 · Phase 2 · registry result, not featured evidence
-8.73 vs -6.29 placebo score @ 5wk10 mg QD
Sensory score
NCT01496365 · Phase 2 · registry result, not featured evidence
-6.56 vs -6.29 placebo score @ 5wk10 mg BID
Sensory score
NCT01496365 · Phase 2 · registry result, not featured evidence
-8.02 vs -6.29 placebo score @ 5wk5mg QD
Sensory score
NCT01496365 · Phase 2 · registry result, not featured evidence
SF-MPQ Affective -1.84 vs -2.1 placebo score @ 5wk15 mg QD
absolute change · score
Affective score
NCT01496365 · Phase 2 · registry result, not featured evidence
show 4 more results
-2.23 vs -2.1 placebo score @ 5wk15 mg BID
Affective score
NCT01496365 · Phase 2 · registry result, not featured evidence
-2.44 vs -2.1 placebo score @ 5wk10 mg QD
Affective score
NCT01496365 · Phase 2 · registry result, not featured evidence
-1.4 vs -2.1 placebo score @ 5wk10 mg BID
Affective score
NCT01496365 · Phase 2 · registry result, not featured evidence
-2.35 vs -2.1 placebo score @ 5wk5mg QD
Affective score
NCT01496365 · Phase 2 · registry result, not featured evidence
SF-MPQ Total -8.71 vs -8.39 placebo score @ 5wk15 mg QD
absolute change · score
Total score
NCT01496365 · Phase 2 · registry result, not featured evidence
show 4 more results
-10.79 vs -8.39 placebo score @ 5wk15 mg BID
Total score
NCT01496365 · Phase 2 · registry result, not featured evidence
-11.16 vs -8.39 placebo score @ 5wk10 mg QD
Total score
NCT01496365 · Phase 2 · registry result, not featured evidence
-7.96 vs -8.39 placebo score @ 5wk10 mg BID
Total score
NCT01496365 · Phase 2 · registry result, not featured evidence
-10.36 vs -8.39 placebo score @ 5wk5mg QD
Total score
NCT01496365 · Phase 2 · registry result, not featured evidence
SF-MPQ VAS -28.73 vs -20.84 placebo score @ 5wk15 mg QD
absolute change · score
VAS pain
NCT01496365 · Phase 2 · registry result, not featured evidence
show 4 more results
-32.82 vs -20.84 placebo score @ 5wk15 mg BID
VAS pain
NCT01496365 · Phase 2 · registry result, not featured evidence
-28.56 vs -20.84 placebo score @ 5wk10 mg QD
VAS pain
NCT01496365 · Phase 2 · registry result, not featured evidence
-25.45 vs -20.84 placebo score @ 5wk10 mg BID
VAS pain
NCT01496365 · Phase 2 · registry result, not featured evidence
-27.4 vs -20.84 placebo score @ 5wk5mg QD
VAS pain
NCT01496365 · Phase 2 · registry result, not featured evidence
SF-MPQ PPI -0.9 vs -0.85 placebo score @ 5wk15 mg QD
absolute change · score
NCT01496365 · Phase 2 · registry result, not featured evidence
show 4 more results
-1.02 vs -0.85 placebo score @ 5wk15 mg BID
NCT01496365 · Phase 2 · registry result, not featured evidence
-1.04 vs -0.85 placebo score @ 5wk10 mg QD
NCT01496365 · Phase 2 · registry result, not featured evidence
-0.73 vs -0.85 placebo score @ 5wk10 mg BID
NCT01496365 · Phase 2 · registry result, not featured evidence
-1 vs -0.85 placebo score @ 5wk5mg QD
NCT01496365 · Phase 2 · registry result, not featured evidence

+ 6 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Crisugabalin's landscape · Mirogabalin's landscape